Article
High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
Molecular and cellular biochemistry - 1 Dec 2020
Chen Chuanhui, Peng Shanshan, Li Penghui, Ma Lin, Gan Xin
Abstract excerpt
Activating mutations within the tyrosine kinase (TK) domain of epidermal growth factor receptor (EGFR) gene are observed in 10 ~ 30% of the patients diagnosed with non-small cell lung cancer (NSCLC), and are causally related to NSCLC initiation and progression. Treatments with tyrosine kinase inhibitors (TKIs) targeting EGFR significantly improve the outcome of NSCLC patients with EGFR mutation, but are often...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.